Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Autor: Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland., Angevin E; Drug Development Department (DITEP), Institut Gustave Roussy, Villejuif, France., Alonso-Gordoa T; Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain., Rohrberg K; Phase 1 Unit, Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Melero I; Oncology and Immunology Department, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain., Mellado B; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Perez-Gracia JL; Oncology and Immunology Department, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain., Tabernero J; Medical Oncology Department, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain., Adessi C; F. Hoffmann-La Roche Ltd, Research & Early Development Oncology, Basel, Switzerland., Boetsch C; F. Hoffmann-La Roche Ltd, Research & Early Development Oncology, Basel, Switzerland., Watson C; A4P Consulting Ltd, Sandwich, United Kingdom., Dal Porto J; Discovery, Genentech, Inc., South San Francisco, California., Dejardin D; Product Development, Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Del Nagro C; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Nicolini V; F. Hoffmann-La Roche Ltd, Research & Early Development Oncology, Basel, Switzerland., Evers S; F. Hoffmann-La Roche Ltd, Research & Early Development Oncology, Basel, Switzerland., Klein C; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Leutgeb B; Product Development Oncology F. Hoffmann-La Roche Ltd, Basel, Switzerland., Pisa P; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Rossmann E; Product Development, Safety Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Saro J; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Umana P; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Charo J; Research & Early Development Oncology, F. Hoffmann-La Roche Ltd, Zurich, Switzerland., Teichgräber V; F. Hoffmann-La Roche Ltd, Research & Early Development Oncology, Basel, Switzerland., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1630-1641.

Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.

Autor: Xiao Y; Corresponding Author: Thomas O'Brien, Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080. obrien.tom@gene.com., Ramiscal J, Kowanetz K, Del Nagro C, Malek S, Evangelista M, Blackwood E, Jackson PK, O'Brien T

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2013 Nov; Vol. 12 (11), pp. 2285-95. Date of Electronic Publication: 2013 Sep 13.